Acurx Pharmaceuticals Inc. - Bathi resik saben saham sajrone 12 wulan pungkasan ACXP

Acurx Pharmaceuticals (ACXP) targets the hospital sector by developing antibiotics for the treatment of severe intestinal infections. The development of irezamicin, supported by the US CDC, provides access to the orphan drug market. High-level biochemical expertise drives R&D development, while the YoY TTM EPS percentage change trend reflects profit dynamics, where the 73.50 metric serves as the target level.
Acurx - rincian analitis lan metrik utama (ACXP)

Assessing the asset quality of Acurx Pharmaceuticals (ACXP) requires an analysis of profitability dynamics. The comparable annual growth of EPS TTM captures the change in net income per share over 12 months, revealing the business's scaling pace. Growth in this indicator confirms the effectiveness of R&D personnel in antibiotic development. It is critical for investors to distinguish a sustainable trend from a speculative spike, as this will prevent overpaying for the asset or freezing capital.